Lineage Cell Therapeutics Inc revenue growth has been varied year-over-year.

What is LCTX's revenue growth rate?

Historical revenue data is available for Lineage Cell Therapeutics Inc to analyze growth trends.

How fast is LCTX earnings growing?

Earnings growth data is available for Lineage Cell Therapeutics Inc analysis.

What is LCTX's profit margin?

Profit margin data is available for Lineage Cell Therapeutics Inc.

LCTX Revenue & Earnings Growth Analysis 2026 - Is Lineage Cell Therapeutics Inc Growing?

Growth Summary

Lineage Cell Therapeutics Inc (LCTX) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.

Over the past 4 years, Lineage Cell Therapeutics Inc has achieved a revenue compound annual growth rate (CAGR) of 41.3%, while earnings have grown at 43.6% CAGR.

Latest Revenue

$9.50M

Net Income

$-18582000.00

5-Year Revenue CAGR

41.3%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Lineage Cell Therapeutics Inc

The chart above illustrates Lineage Cell Therapeutics Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Lineage Cell Therapeutics Inc's business.

Profit Margin Trends

How efficiently Lineage Cell Therapeutics Inc converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Lineage Cell Therapeutics Inc retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$-0.06

Current: $-0.09

EPS Estimate 2027

$-0.08

29.2% expected growth

Price Target

$4.50

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Lineage Cell Therapeutics Inc to continue focusing on sustainable operations. The consensus analyst rating is 4.4286 based on 7 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Lineage Cell Therapeutics Inc (LCTX) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 41.3% CAGR over 4 years
Profitability: shows the company is investing in growth over short-term profits
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Lineage Cell Therapeutics Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.